Slide 1: Acquisition of Array BioPharma
Acquisition of Array BioPharma June 17, 2019
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, Pfizer, Array BioPharma and Pfizer’s planned acquisition of Array BioPharma, including its potential benefits, anticipated roya
Slide 3: Important Information About the Tender Offer
Important Information About the Tender Offer The tender offer referenced in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender off
Slide 4: Acquisition Aligns with Pfizer's Strategic Priorities
Acquisition Aligns with Pfizer’s Strategic Priorities • Deploy capital to efficiently create meaningful shareholder value • Bias towards “bolt-on” deals with potential for mid to long-term value creation and revenue and earnings growth • Strengthen individual businesses with capabilities and flagshi
Slide 5: Array BioPharma Represents an Attractive Acquisition With Multiple Value Drivers
Array BioPharma Represents an Attractive Acquisition With Multiple Value Drivers Proposed acquisition strengthens our innovative biopharmaceutical business, expected to accelerate its growth trajectory particularly in the long term 1 Approved Combination Therapy in Melanoma • Combination in 1L BRAF-
Slide 6: Transaction Overview
Transaction Overview Purchase $48 per share; 100% cash consideration Price Transaction value of approximately $11.4 billion (inclusive of net debt) Expected to be approximately $0.04-$0.05 dilutive to adjusted diluted EPS* in each of 2019 and 2020, neutral in 2021, Financial and accretive begi
Slide 7: BRAFTOVI and MEKTOVI are Targeted Medicines with Best-in-Class Potential
BRAFTOVI and MEKTOVI are Targeted Medicines with Best-in-Class Potential in BRAF-mutant Metastatic Melanoma and mCRC BRAF-mutant Metastatic Melanoma BRAF-mutant mCRC Melanoma is one of the top 3 most common cancers CRC is the 3rd most common cancer in the world and among those aged 20-39(1) the
Slide 8: Interim Analysis from BEACON 2/3L BRAF-Mutated mCRC Trial
Interim Analysis from BEACON 2/3L BRAF-Mutated mCRC Trial Showed Statistically Significant Improvement in ORR and OS vs. Control Among 2L patients ORR with the triplet was 34% Source: Array BioPharma Investor Presentation, June 2019. ORR = Overall Response Rate; OS = Overall Survival
Slide 9: Advancing Leadership for BRAF/MEK-inhibitors
Advancing Leadership for BRAF/MEK-inhibitors Expected Data Readout Milestones ANCHOR BEACON 1L BRAF- Additional lifecycle 2L+ BRAF- mutant mCRC opportunities mutant COLUMBUS mCRC 1L BRAF- BRAF-mutant NSCLC / Other mutant Early 2020s* Melanoma High Risk Adjuvant 2019 BRAF-mutant CRC Combination T
Slide 10: Highly Productive Research Engine
Highly Productive Research Engine Product Licensee(s) Indication(s) Phase • Established track record of success in research and * BRAF+ Melanoma; BRAF+ mCRC; Approved / Phase 3 Other Cancers development Solid Tumors with NTRK Fusions Approved • Large portfolio of (Tissue Agnostic) attractive medicin
Slide 11: Key Takeaways
Key Takeaways Consistent with Pfizer’s purpose: Breakthroughs that change patients’ lives Expands Pfizer’s capabilities in Oncology and brings a range of opportunities to create value Sets the stage to establish leadership for the treatment of people with BRAF-mutated colorectal cancer Augme
Slide 12: Q&A
Q&A